Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | IKBKB | O14920 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11622676 | 0.98 | TARBP2 (0.62) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL6583843 | 0.88 | POLB (0.64) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL167906 | 0.86 | IKBKB (0.69) | TARBP2KDM4EGAAPOLBTDP1 | |
| Hydrochloric Acid SCHEMBL11621803 | 0.86 | TARBP2 (0.64) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL893186 | 0.86 | TARBP2 (0.61) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL9832175 | 0.85 | L3MBTL1 (0.55) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL9832492 | 0.85 | TARBP2 (0.68) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL20022402 | 0.84 | IKBKB (0.58) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL10590839 | 0.84 | KDM4E (0.58) | TARBP2KDM4EGAAPOLBTDP1 | |
| SCHEMBL10590832 | 0.84 | KDM4E (0.58) | TARBP2KDM4EGAAPOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197875-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | claimed |
| WO-2009037222-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | claimed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-6946462-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | claimed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | claimed |
| WO-2005019168-A2 | FLUORINATED LYSINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HAAG RAINER (DE) | 2004-09-30 | — | — | US | claimed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | claimed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | claimed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | claimed |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2003-07-24 | — | — | US | claimed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | claimed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | claimed |
| CN-1350458-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | CN | claimed |
| WO-2015069011-A1 | NOVEL COMPOUND, METHOD FOR PREPARATION THEREOF, AND ANTIFUNGAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-14 | — | — | WO | disclosed |
| US-8748426-B2 | Inhibitors of diacylglycerol acyl transferase | Piramal Enterprises Limited (IN) | 2014-06-10 | — | — | US | disclosed |
| WO-1998004257-A1 | PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5700821-A | INHIBIT CELL PROLIFERATION | UNIVERSITY OF PITTSBURGH (US) | 1997-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | DPP4, DPP7, ALPI | TARBP2 4389/4885KDM4E 196/4885GAA 535/4885 |
| US-20040192744-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | TARBP2 4743/4885KDM4E 2857/4885GAA 612/4885 |
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TARBP2 2012/4885KDM4E 917/4885GAA 71/4885 |
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | TARBP2 4816/4885KDM4E 956/4885GAA 201/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | TARBP2 1959/4885KDM4E 875/4885GAA 61/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TARBP2 2012/4885KDM4E 917/4885GAA 71/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TARBP2 2012/4885KDM4E 917/4885GAA 71/4885 |
| US-20030139404-A1 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | NAT1, CYP1A1, UGT1A1 | TARBP2 4743/4885KDM4E 2857/4885GAA 612/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TARBP2 2012/4885KDM4E 917/4885GAA 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.